

SDX | SOLUTION DIAGNOSTICS

Empowering Healthcare, one diagnostic at a time, through accessible and affordable solutions.

Founded 2023
 Website www.solutiondx.com
 HQ Salt Lake City, UT
 Type Consumer Diagnostics

Investment

Series Seed
 Raise \$3M
 Capital Raised \$0.6M
 Minimum \$100K

Use of Funds:

- Clinical and Regulatory 83%
- Company Systems 3%
- Headcount 7%



Team



Chiao-ih Hui
 Founder and CEO



Duke Heninger
 Chief Financial Officer



Matthew McGaw
 VP Business Development



Marcus Osborne
 Strategic Advisor

Overview

Solution Diagnostics is currently conducting clinical trials in the US for 4SureRapid™ 4-in-1 Rapid Antigen Test for COVID-19, Flu A, Flu B, and RSV. Walmart and CVS are working towards private-labeling the test and other Retailers are waiting to purchase and include in their stores.

Highlights


- Immediate sales channel of Retail Market is over 15,000 retail locations
- Technical partner is publicly-traded company in Taiwan founded in 1976

Competition

The only other rapid antigen OTC tests detect COVID-19 only, while tests that include COVID-19, Flu A, Flu B, and RSV require a minimum of 1-2 days after receiving the sample in the lab.

Market

Total Addressable Market: \$11B Annually



- Retailer 74%
- Clinics 8%
- Prisons 8%
- Schools 6%
- Telehealth 4%

Financials

- Based upon Retailer forecasts, financial forecast assumes 400 tests / month / store. Not including respiratory illness season sees a ramp of 1200 tests / month / store
- PO Financing for COGS already lined up

PRO-FORMA	2024	2025	2026	2027
Revenue (K)	\$25,600	\$96,000	\$232,000	\$422,400
COGS (K)	\$13,152	\$49,320	\$119,190	\$217,008
Gross Profit (K)	\$12,488	\$46,680	\$112,810	\$205,392
Gross Margin %	48.63%	48.63%	48.63%	48.63%